Innate Pharma (IPHA) Enterprise Value (2017 - 2025)
Innate Pharma (IPHA) has disclosed Enterprise Value for 8 consecutive years, with -$15.4 million as the latest value for Q4 2024.
- For the quarter ending Q4 2024, Enterprise Value rose 79.78% year-over-year to -$15.4 million, compared with a TTM value of -$76.0 million through Dec 2023, changed N/A, and an annual FY2024 reading of -$15.6 million, up 79.63% over the prior year.
- Enterprise Value was -$15.4 million for Q4 2024 at Innate Pharma, up from -$76.0 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$15.4 million in Q4 2024 and bottomed at -$180.8 million in Q4 2020.
- Average Enterprise Value over 5 years is -$81.7 million, with a median of -$76.0 million recorded in 2023.
- The sharpest move saw Enterprise Value skyrocketed 85.16% in 2022, then tumbled 331.4% in 2023.
- Year by year, Enterprise Value stood at -$180.8 million in 2020, then surged by 34.35% to -$118.7 million in 2021, then surged by 85.16% to -$17.6 million in 2022, then crashed by 331.4% to -$76.0 million in 2023, then skyrocketed by 79.78% to -$15.4 million in 2024.
- Business Quant data shows Enterprise Value for IPHA at -$15.4 million in Q4 2024, -$76.0 million in Q4 2023, and -$17.6 million in Q4 2022.